Maxim Group Boosts MediWound (NASDAQ:MDWD) Price Target to $30.00

MediWound (NASDAQ:MDWD) had its price target boosted by investment analysts at Maxim Group from $25.00 to $30.00 in a research note issued on Tuesday, MarketBeat.com reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective points to a potential upside of 47.57% from the stock’s previous close.

Several other analysts have also recently commented on MDWD. HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of MediWound in a report on Thursday, May 30th. StockNews.com raised shares of MediWound to a “sell” rating in a research note on Wednesday, July 3rd.

MediWound Stock Down 2.2 %

MDWD opened at $20.33 on Tuesday. MediWound has a 12-month low of $7.10 and a 12-month high of $24.00. The firm has a market capitalization of $188.74 million, a P/E ratio of -14.73 and a beta of 0.81. The stock has a fifty day moving average of $16.79 and a 200-day moving average of $15.34.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.01. MediWound had a negative return on equity of 21.67% and a negative net margin of 64.24%. The firm had revenue of $4.96 million during the quarter, compared to the consensus estimate of $4.65 million. On average, analysts expect that MediWound will post -1.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MediWound

Large investors have recently made changes to their positions in the company. Silverberg Bernstein Capital Management LLC raised its position in MediWound by 7.8% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock valued at $1,214,000 after acquiring an additional 6,200 shares in the last quarter. Sargent Investment Group LLC raised its holdings in shares of MediWound by 7.0% during the 4th quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock valued at $1,111,000 after purchasing an additional 7,125 shares in the last quarter. Rosalind Advisors Inc. raised its holdings in shares of MediWound by 5.7% during the 2nd quarter. Rosalind Advisors Inc. now owns 513,490 shares of the biopharmaceutical company’s stock valued at $7,969,000 after purchasing an additional 27,500 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of MediWound in the 1st quarter valued at $427,000. Finally, Yelin Lapidot Holdings Management Ltd. boosted its holdings in MediWound by 45.7% in the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock worth $1,276,000 after purchasing an additional 39,348 shares in the last quarter. Institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.